Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings - 14/03/24
, Hanh Bui, MD, MPH b, A John Camm, MD c, Benoit Coutu, MD d, Peter A. Noseworthy, MD, MBA e, Maria Leonor Parody, MD f, Samuel F Sears, PhD g, Narendra Singh, MD h, Juan Agudelo Uribe, MD i, John Vyselaar, MD j, Sarah Omodele, DNP k, Silvia Shardonofsky, MD, MSc k, David B. Bharucha, MD, PhD l, Bruce Stambler, MD mRésumé |
Background |
Paroxysmal supraventricular tachycardia (PSVT) is a common episodic arrhythmia characterized by unpredictable onset and burdensome symptoms including palpitations, dizziness, chest pain, distress, and shortness of breath. Treatment of acute episodes of PSVT in the clinical setting consists of intravenous adenosine, beta-blockers, and calcium channel blockers (CCBs). Etripamil is an intranasally self-administered L-type CCB in development for acute treatment of AV-nodal dependent PSVT in a nonmedical supervised setting.
Methods |
This paper summarizes the rationale and study design of NODE-303 that will assess the efficacy and safety of etripamil. In the randomized, double-blinded, placebo-controlled, Phase 3 RAPID trial, etripamil was superior to placebo in the conversion of single PSVT episodes by 30 minutes post initial dose when administered in the nonhealthcare setting; this study required a mandatory and observed test dosing prior to randomization. The primary objective of NODE-303 is to evaluate the safety of symptom-prompted, self-administered etripamil for multiple PSVT episodes in real-world settings, without the need for test dosing prior to first use during PSVT. Secondary endpoints include efficacy and disease burden. Upon perceiving a PSVT episode, the patient applies an electrocardiographic monitor, performs a vagal maneuver, and, if the vagal maneuver is unsuccessful, self-administers etripamil 70 mg, with an optional repeat dose if symptoms do not resolve within 10 minutes after the first dose. A patient may treat up to four PSVT episodes during the study. Adverse events are recorded as treatment-emergent if they occur within 24 hours after the administration of etripamil.
Results |
Efficacy endpoints include time to conversion to sinus rhythm within 30 and 60 minutes after etripamil administration, and the proportion of patients who convert at 3, 5, 10, 20, 30, and 60 minutes. Patient-reported outcomes are captured by the Brief Illness Perception Questionnaire, the Cardiac Anxiety Questionnaire, the Short Form Health Survey 36, the Treatment Satisfaction Questionnaire for Medication and a PSVT survey.
Conclusions |
Overall, these data will support the development of a potentially paradigm-changing long-term management strategy for recurrent PSVT.
Le texte complet de cet article est disponible en PDF.Plan
Vol 270
P. 55-61 - avril 2024 Retour au numéro
Article précédent
- Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank
- Konstantin A. Krychtiuk, Tomas LG Andersson, Ulrike Bodesheim, Javed Butler, Lesley H. Curtis, Mitchell Elkind, Adrian F. Hernandez, Christoph Hornik, Gary H. Lyman, Pooja Khatri, Michael Mbagwu, Masahiro Murakami, Gwen Nichols, Lothar Roessig, Anne Quinn Young, Richard L. Schilsky, Neha Pagidipati
- TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and multivessel or advanced coronary disease: The transcatheter valve and vessels trial (TCW trial): Design and rationale
- Elvin Kedhi, Andi Rroku, Rik S. Hermanides, Jan Henk Dambrink, Sandeep Singh, Jurriën Ten Berg, Dirk-Jan van Ginkel, Martin Hudec, Giovanni Amoroso, Ignacio J. Amat-Santos, Martin Andreas, Rui Campante Teles, Guillaume Bonnet, Eric Van Belle, Lenard Conradi, Leen van Garsse, Wojtek Wojakowski, Vasileious Voudris, Jerzy Sacha, Pavel Cervinka, Erik Lipsic, Samer Somi, Luis Nombela-Franco, Sonja Postma, Kerstin Piayda, Giuseppe De Luca, Krzysztof Malinofski, Thomas Modine
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?